BULLETIN

NO. 37

February 2, 2017

Dear Provider:

Benefit List Update

The following products have been added to the Newfoundland and Labrador Prescription Drug Program (NLPDP) benefit list effective February 1, 2017.

Special Authorization

NINTEDANIB (OFEV 100mg, 150mg capsule)
DIN 02443066, DIN 02443074

Adult patients with a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF):

- Diagnosis confirmed by a respirologist and a high-resolution CT scan within the previous 24 months.
- All other causes of restrictive lung disease (e.g. collagen vascular disorder or hypersensitivity pneumonitis) should be excluded.
- Mild to moderate IPF is defined as forced vital capacity (FVC) greater than or equal to 50% of predicted.
- Patient is under the care of a physician with experience in IPF

Initial approval period: 7 months (allow 4 weeks for repeat pulmonary function tests)

Initial renewal criteria (at 6 months):

Patients must NOT demonstrate progression of disease defined as an absolute decline in percent predicted FVC of ≥ 10% from initiation of therapy until renewal (initial 6 month treatment period). IF a patient has experienced progression as defined above, then the results should be validated with a confirmatory pulmonary function test conducted 4 weeks later.

Approval period: 6 months

Second and subsequent renewals (at 12 months and thereafter):

Patients must NOT demonstrate progression of disease defined as an absolute decline in percent predicted FVC of ≥ 10% within any 12 month period. If a patient has experienced progression as defined above, then the results should be validated with a confirmatory pulmonary function test conducted 4 weeks later.

Approval period: 12 months

Exclusion criteria:
Combination use of Ofev (nintedanib) and Esbriet (pirfenidone) will not be funded.

Notes:
Patients who have experienced intolerance or failure to Ofev (nintedanib) or Esbriet (pirfenidone) will be considered for the alternate agent provided that the patient continues to meet the above coverage criteria.

If you have any questions concerning these changes, please feel free to contact the Pharmaceutical Services Division at 1-888-222-0533 or 709-729-6507.

ECS170202